China’s gene sequencing equipment champion seeks public listing amidst sprawling global patent battle
BGI and its sequencer-manufacturing subsidiary MGI Tech made over 70% of their revenue abroad last year, but face over 20 patent assertions in overseas markets
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now